NEW YORK (GenomeWeb) – MDxHealth today reported preliminary earnings for 2015 showing it has met its guidance for revenue and test volume.
The multinational healthcare company said it expects 2015 revenue of $16 million to $20 million, and 15,000 to 17,000 tests performed during the year. In Q4, the firm's ConfirmMDx prostate cancer test volume increased approximately 50 percent compared to the year-ago quarter, to more than 5,000 tests.
"Our continued focus on promoting broad-based adoption of ConfirmMDx in the US is producing strong results," MDxHealth CEO Jan Groen said in a statement. "The sharp increase in case volumes is a good indicator of our performance trajectory, and further demonstrates that strategic investments in our managed care team and sales force over the last year have proved effective."
The company will release itsfinancial results for 2015 on Feb. 18.